Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05502523 · ClinicalTrials.gov registry record · NA

The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer

A NA study of Lung Non-Small Cell Carcinoma and Stage III Lung Cancer AJCC v8, sponsored by Thomas Jefferson University.

Recruiting
Registry status
NA
Development phase
100
Enrollment target
4
Study locations

NCT05502523: Recruiting NA study of Lung Non-Small Cell Carcinoma and Stage III Lung Cancer AJCC v8, sponsored by Thomas Jefferson University.

NCT05502523 is a NA study of Lung Non-Small Cell Carcinoma and Stage III Lung Cancer AJCC v8 that is actively recruiting participants, run by Thomas Jefferson University. The registered enrollment target is 100 participants, below the 158-participant average among 47 other Lung Non-Small Cell Carcinoma trials with a reported enrollment target (37% lower). The trial reports 4 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05502523, a NA study of Lung Non-Small Cell Carcinoma and Stage III Lung Cancer AJCC v8, is actively recruiting participants, sponsored by Thomas Jefferson University.

RECRUITING
Registry status
NA
Development phase
100 participants
Enrollment target
4
Study locations

Study Summary

This clinical trial compares the effect of pulmonary vein-first surgical technique to pulmonary artery-first surgical technique in decreasing circulating tumor cell deoxyribonucleic acid (ctDNA) in patients with stage I-III non-small cell lung cancer. Pulmonary vein first and pulmonary artery first surgical techniques are standard surgical techniques for the division of the blood vessels during lung resection surgery. Pulmonary vein-first surgical technique may reduce the risk of shedding tumor cells during surgery and influence long term overall survival.

Primary Outcome

Stratified by surgical vascular division technique. A peripheral blood sample will be taken at the time of surgery to determine baseline ctDNA status. Following surgical resection a blood sample will be taken at specified time points (postoperative day 2; postoperative day 14) to determine ctDNA levels compared to baseline. The difference in the proportion of patients who have positive ctDNA status between those undergoing division/ligation in a "pulmonary-vein first" technique compared to a "pu

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Pulmonary Artery-First Surgical Technique

Study Locations (4)

Pennsylvania

  • Abington Memorial Hospital - Abington
  • Jefferson Health Northeast - Philadelphia
  • Thomas Jefferson University Hospital - Philadelphia
  • Asplundh Cancer Pavilion at Jefferson Health - Willow Grove

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2022-08-31
Est. Completion 2029-01-01
Phase NA
Thomas Jefferson University

292 total trials

What NCT05502523 shows while recruiting

NCT05502523 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 158-participant average among 47 other Lung Non-Small Cell Carcinoma trials with a reported enrollment target (37% lower).

The record links to 4 conditions, with Lung Non-Small Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Biospecimen Collection is the first listed.

NCT05502523 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT05502523 about?

NCT05502523 is a clinical study titled "The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer". This clinical trial compares the effect of pulmonary vein-first surgical technique to pulmonary artery-first surgical technique in decreasing circulating tumor cell deoxyribonucleic acid (ctDNA) in patients with stage I-III non-small cell lung cancer. Pulmonary vein first and pulmonary artery first ...

What is the current status of trial NCT05502523?

This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2022-08-31. Estimated completion is 2029-01-01.

What conditions does trial NCT05502523 study?

This clinical trial studies the following conditions: Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage I Lung Cancer AJCC v8.

What interventions are being tested in trial NCT05502523?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Pulmonary Artery-First Surgical Technique (PROCEDURE).

Who is sponsoring clinical trial NCT05502523?

This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05502523 being conducted?

This trial has 4 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lung Non-Small Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05502523's enrollment target sits among peer trials

100 14th of 47 higher than 32 of 47 other Lung Non-Small Cell Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lung Non-Small Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05502523, the US trial registry maintained by the National Library of Medicine. NCT05502523 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.